IFM Investors 13F: New $4.7M Stake in Roivant Sciences (ROIV)

IFM Investors established a new stake in Roivant Sciences Ltd. ROIV, picking up 128,826 shares worth about $4.71 million. The activity was revealed in a Form 13F filing with the Securities and Exchange Commission on October 14, 2026. Because 13F filings look backward, the report reflects holdings as of the end of the reporting period and may not represent the investor's current position today.

Inside IFM Investors's Roivant Sciences Trade

The fund opened a brand-new position in the biotechnology firm, adding 128,826 shares to its portfolio without any prior holding. The reported value of the stake stood at $4,711,167 at the time of the filing. Institutional reports like this provide a snapshot of portfolio moves from past months rather than real-time trading.

Other Institutional Activity in Roivant Sciences

Other major institutional managers made significant adjustments to their Roivant Sciences holdings during the same reporting window. FMR, LLC grew its holdings by 3041189 shares, ending with 81020390 shares worth about $2716613577.0. Blackrock Inc. grew its holdings by 3982797 shares, ending with 48236091 shares worth about $1617356072.0. Morgan Stanley reduced its holdings by 9235891 shares, ending with 42592905 shares worth about $1428140052.0, a 17.8% decrease. QVT Financial LP reduced its holdings by 1439287 shares, ending with 23723074 shares worth about $795434642.0, a 5.7% decrease. Vanguard Capital Management LLC grew its holdings by 1443447 shares, ending with 22123198 shares worth about $741790801.0, a 7.0% increase.

Roivant Sciences Ltd. Stock Down 2.1%

Roivant Sciences shares recently traded around $33.33 as of October 16, 2026. The stock sits about 9.1% below its 50-day moving average of $36.67 and roughly 8.5% above its 200-day moving average of $30.73. Over the past year, shares have ranged from a low of $16.88 to a high of $42.50.

Recent Earnings

For its trailing-twelve-month period, Roivant Sciences reported $7,532,000 in revenue alongside an EPS of -$0.51. The company posted a net margin of 0.0% and a return on equity of -8.5%. The next corporate earnings release is scheduled for November 9, 2026.

Insider Buying and Selling at Roivant Sciences Ltd.

Company insiders executed several transactions prior to the filing. On September 8, 2026, Director Meghan Fitzgerald sold 20,000 shares at an average price of $39.90 for a total value of $798,000. On September 15, 2026, Director Melissa B Epperly sold 4,938 shares valued at $196,230. On the same day, Director Meghan Fitzgerald sold 5,112 shares worth $203,152. Later, on October 1, 2026, Director Melissa B Epperly sold 17,750 shares for $640,861.

Analysts Set New Price Targets

Wall Street firms adjusted their views on the stock ahead of the filing. On September 8, 2026, HC Wainwright & Co. maintained its Buy rating and raised its price target from $41.00 to $47.00. On September 9, 2026, TD Cowen maintained a Buy rating while lifting its target from $50.00 to $55.00. On September 9, 2026, Guggenheim maintained a Buy rating and raised its target from $42.00 to $46.00. On September 17, 2026, Stifel initiated coverage with a Buy rating and a $51.00 price target. Later, on October 12, 2026, Wolfe Research downgraded the stock to Peer Perform. Overall, the stock carries a consensus strong buy rating with an average analyst price target of $48.27 across 11 opinions.

About Roivant Sciences

Headquartered in London, United Kingdom, Roivant Sciences is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing new medicines and technologies. The firm operates with 721 employees and a market capitalization of roughly $24.22 billion. Its clinical pipeline and drug development progress remain key areas of focus for institutional investors following these recent portfolio adjustments.

Bottom Line

IFM Investors's new stake highlights institutional interest in the biotech firm, though the disclosed figures reflect past activity rather than current holdings. Observers will look ahead to the company's upcoming earnings report on November 9, 2026, for further updates on its clinical and financial progress. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.